相关实验视频

Updated: Jan 9, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

[前列腺素合成酶在致癌过程中的作用]

Yuka Sasaki^1,2

¹Department of Health Chemistry, Graduate School of Pharmacy, Showa Medical University.

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

|November 30, 2025

概括

微粒体前列腺素E合成酶-1 (mPGES-1) 和前列腺素合成酶 (PGIS) 是前列腺素合成中的关键酶. 抑制mPGES-1可能为预防癌症提供比NSAID更安全的替代品,而PGIS显示在癌症发生过程中具有组织特异性的作用.

科学领域:

生物化学生物化学
分子生物学分子生物学
癌症研究癌症研究

背景情况:

前列腺素 (PGs) 是由酸衍生的脂质化合物,通过循环氧化酶 (COX) 和PG合成酶合成.
由炎症刺激诱导的COX-2促进炎症和癌症的发展.
非类固醇抗炎药物 (NSAIDs) 抑制COX以抑制炎症,并且已经显示出预防结肠癌的潜力,但长期使用会导致副作用.

研究的目的:

审查PG合成酶在COX下游的癌症发生中的作用.
讨论抑制癌症发展的新型药物标.
探索mPGES-1和PGIS作为潜在的治疗点.

主要方法:

对前列腺素合成酶及其在癌症中的作用现有文献的综述.
来自mPGES-1淘汰赛小鼠模型的数据分析.
对研究不同类型癌症中PGIS功能的研究进行了审查.

主要成果:

mPGES-1和PGIS与COX-2相结合,分别产生PGE2和PGI2,导致炎症.
结肠,皮肤和膀癌发生在mPGES-1淘汰小鼠中被抑制.
mPGES-1 缺乏并没有引起异常,这表明mPGES-1 抑制剂是潜在的癌症抑制剂.
PGIS抑制了结肠癌,但没有影响皮肤致癌,这表明其具有组织特异性的作用.

结论:

由于其有针对性的作用和缺乏不良影响,mPGES-1抑制剂代表了对抗癌症的NSAIDs有希望的替代品.
在各种组织中,PGIS对致癌产生具有差异性影响,突出显示了它在癌症进展中的复杂作用.
准特定的PG合成酶为癌症治疗和预防提供了一种细微的方法.

关键词:

癌症癌症癌症癌症癌症简介:前环素是一种前环素.的前列腺素 (PG) 的前列腺素 (PG).

更多相关视频

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

相关概念视频

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Cancer-Critical Genes I: Proto-oncogenes

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Gastritis-II: Pathophysiology

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...